Abstract
The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Current Molecular Medicine
Title: RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Volume: 11 Issue: 8
Author(s): K. J. Doherty, C. McKay, K. K. Chan and M. K. El-Tanani
Affiliation:
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Abstract: The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Export Options
About this article
Cite this article as:
J. Doherty K., McKay C., K. Chan K. and K. El-Tanani M., RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins, Current Molecular Medicine 2011; 11 (8) . https://dx.doi.org/10.2174/156652411797536688
DOI https://dx.doi.org/10.2174/156652411797536688 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene
Current Drug Metabolism ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children
Reviews on Recent Clinical Trials RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology Potential Lithium and Fluoride Interactions in Studies of Glycogen Synthase Kinase-3
Current Enzyme Inhibition Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Microtubule-targeting Anticancer Agents from Marine Natural Substance
Anti-Cancer Agents in Medicinal Chemistry Strategies and Techniques for Multi-Component Drug Design from Medicinal Herbs and Traditional Chinese Medicine
Current Topics in Medicinal Chemistry Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Extracellular Signals for Guiding Mesenchymal Stem Cells Osteogenic Fate
Current Stem Cell Research & Therapy Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals